Related references
Note: Only part of the references are listed.The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland's Health System?
James F. O'Mahony et al.
PHARMACOECONOMICS (2016)
Opportunity costs and local health service spending decisions: a qualitative study from Wales
Sarah Karlsberg Schaffer et al.
BMC HEALTH SERVICES RESEARCH (2016)
Evolocumab and alirocumab: exploring original procurement models to manage the reimbursement of these innovative treatments
Andrea Messori
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2016)
Lowering the High Cost of Cancer Drugs-II
Andrea Messori et al.
MAYO CLINIC PROCEEDINGS (2016)
Comment on: Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review
Angelo Claudio Palozzo et al.
PHARMACOECONOMICS (2016)
Criteria for Drug Pricing: Preliminary Experiences with Modeling the Price-Volume Relationship
Andrea Messori
SCIENTIA PHARMACEUTICA (2016)
Newest Treatments for Hepatitis C: How Can We Manage Sustainability?
Andrea Messori
CLINICAL INFECTIOUS DISEASES (2015)
Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs
Peter B. Bach et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Value-Based Cancer Care
Robert C. Young
NEW ENGLAND JOURNAL OF MEDICINE (2015)
New Math on Drug Cost-Effectiveness
Peter B. Bach
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review
Bonny Parkinson et al.
PHARMACOECONOMICS (2015)
New cholesterol drugs are overpriced, independent analysis finds
Michael McCarthy
BMJ-BRITISH MEDICAL JOURNAL (2015)
New cholesterol drugs are overpriced, independent analysis finds
Michael McCarthy
BMJ-BRITISH MEDICAL JOURNAL (2015)
Can the Real Opportunity Cost Stand Up: Displaced Services, the Straw Man Outside the Room
Simon Eckermann et al.
PHARMACOECONOMICS (2014)
Value based pricing: can it work?
James Raftery
BMJ-BRITISH MEDICAL JOURNAL (2013)
Value-based pricing: time for a NICEr way of measuring health?
Henry Lee et al.
LANCET (2011)
The opportunity cost of cancer care: a statement from NICE
Michael D. Rawlins et al.
LANCET ONCOLOGY (2011)
Value-based drug system proposed in UK
Roger Collier
CANADIAN MEDICAL ASSOCIATION JOURNAL (2010)
Role of budget impact in drug reimbursement decisions
Joshua Parsons Cohen et al.
JOURNAL OF HEALTH POLITICS POLICY AND LAW (2008)
The Office of Fair Trading report: a prescription for value-based drug pricing
Rubin Minhas et al.
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE (2007)